Literature DB >> 11917281

Radiation pneumonitis and early circulatory cytokine markers.

Yuhchyau Chen1, Jacqueline Williams, Ivan Ding, Eric Hernady, Weimin Liu, Therese Smudzin, Jacob N Finkelstein, Philip Rubin, Paul Okunieff.   

Abstract

Radiation pneumonitis is a distinct clinical entity that differs from other pulmonary symptoms such as allergic pneumonitis, chemical pneumonitis, or pneumonia by various infectious agents. Recent research has supported the mechanism of cellular interaction between lung parenchymal cells and circulating immune cells mediated through a variety of cytokines including proinflammatory cytokines, chemokines, adhesion molecules, and profibrotic cytokines. Identifying reliable biomarkers for radiation pneumonitis will allow us to identify individuals at risk for pneumonitis before or during the early stage of therapy. Prospective blood sampling, scoring of respiratory symptoms, and chest imaging were conducted for patients receiving thoracic radiotherapy for malignancy. Serial plasma specimens were analyzed for circulating cytokine changes before, during, and up to 12 weeks after radiation. Radiation pneumonitis was diagnosed using National Cancer Institute (NCI) common toxicity criteria. Cytokine analysis was assayed for interleukin 1alpha (IL-1alpha), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), E-selectin, L-selectin, transforming growth factor beta1 (TGF-beta1), and basic fibroblast growth factor (bFGF) using enzyme linked immmunosorbant assay (ELISA). Twenty-four patients had clinical follow-up longer than 12 months after radiotherapy. Thirteen had symptomatic pneumonitis (NCI grade 2). The peak incidence of symptoms was between 6 and 13 weeks after radiotherapy. Six patients had only radiographic infiltrates (NCI grade 1). Five patients did not have clinical or radiographic pneumonitis. Both IL-1alpha and IL-6 levels were significantly higher before, during, and after radiotherapy for those who had pneumonitis. The pattern of changes of MCP-1, E-selectin, L-selectin, TGF-beta1, and bFGF varied, but none of these cytokines correlated with radiation pneumonitis. Analysis of a panel of circulating cytokines with different putative functions in radiation pulmonary injury identified IL-1alpha and IL-6 as early circulating cytokine markers for radiation pneumonitis. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917281     DOI: 10.1053/srao.2002.31360

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  62 in total

1.  Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer?

Authors:  Elizabeth S Evans; Zafer Kocak; Su-Min Zhou; Daniel A Kahn; Hong Huang; Donna R Hollis; Kim L Light; Mitchell S Anscher; Lawrence B Marks
Journal:  Cytokine       Date:  2006-09-18       Impact factor: 3.861

2.  Cellular inflammatory infiltrate in pneumonitis induced by a single moderate dose of thoracic x radiation in rats.

Authors:  Sara Szabo; Swarajit N Ghosh; Brian L Fish; Sreedhar Bodiga; Rade Tomic; Gagan Kumar; Natalya V Morrow; John E Moulder; Elizabeth R Jacobs; Meetha Medhora
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

3.  Early alterations in cytokine expression in adult compared to developing lung in mice after radiation exposure.

Authors:  Carl J Johnston; Eric Hernady; Christina Reed; Sally W Thurston; Jacob N Finkelstein; Jacqueline P Williams
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

4.  Lipopolysaccharide-binding protein is efficient in biodosimetry during radiotherapy of lung cancer.

Authors:  Justyna Chalubinska-Fendler; Wojciech Fendler; Michal Spych; Krystyna Wyka; Jolanta Luniewska-Bury; Jacek Fijuth
Journal:  Biomed Rep       Date:  2016-08-08

5.  Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Authors:  Jinbo Yue; Qiuling Shi; Ting Xu; Melenda Jeter; Ting-Yu Chen; Ritsuko Komaki; Daniel R Gomez; Tinsu Pan; Charles S Cleeland; Zhongxing Liao; Xin Shelley Wang
Journal:  Qual Life Res       Date:  2018-03-16       Impact factor: 4.147

6.  The Influence of Radiotherapy on AIM2 Inflammasome in Radiation Pneumonitis.

Authors:  Qianyu Zhang; Qinyong Hu; Yuxin Chu; Bin Xu; Qibin Song
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

7.  Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.

Authors:  T Schneider; A Sevko; C P Heussel; L Umansky; P Beckhove; H Dienemann; S Safi; J Utikal; H Hoffmann; V Umansky
Journal:  Clin Exp Immunol       Date:  2015-04-15       Impact factor: 4.330

8.  Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.

Authors:  Toshiyuki Ogata; Hideya Yamazaki; Teruki Teshima; Ayaka Kihara; Yuko Suzumoto; Takehiro Inoue; Norihiro Nishimoto; Nariaki Matsuura
Journal:  Radiat Oncol       Date:  2010-04-07       Impact factor: 3.481

9.  Predictive factors of radiation-induced skin toxicity in breast cancer patients.

Authors:  Miao-Fen Chen; Wen-Cheng Chen; Chia-Hsuan Lai; Chao-Hsiung Hung; Kuo-Chi Liu; Yin-Hsuan Cheng
Journal:  BMC Cancer       Date:  2010-09-23       Impact factor: 4.430

10.  The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients.

Authors:  Ji-Yoon Kim; Yeon-Sil Kim; Young-Kyoon Kim; Hyun-Jin Park; Seung-Joon Kim; Jin-Hyoung Kang; Young-Pil Wang; Hong-Seok Jang; Sang-Nam Lee; Sei-Chul Yoon
Journal:  Radiat Oncol       Date:  2009-11-27       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.